Last reviewed · How we verify
JNJ-90301900 (NBTXR3)
NBTXR3 is a nanoparticle hafnium oxide that concentrates radiation dose within tumor cells, enhancing the cytotoxic effects of radiotherapy.
NBTXR3 is a nanoparticle hafnium oxide that concentrates radiation dose within tumor cells, enhancing the cytotoxic effects of radiotherapy. Used for Locally advanced squamous cell carcinoma of the head and neck (in combination with radiotherapy), Soft tissue sarcoma (in combination with radiotherapy).
At a glance
| Generic name | JNJ-90301900 (NBTXR3) |
|---|---|
| Also known as | Functionalized hafnium oxide nanoparticles, NBTXR3 |
| Sponsor | Johnson & Johnson Enterprise Innovation Inc. |
| Drug class | Nanoparticle radiosensitizer |
| Target | Hafnium oxide nanoparticles (radiation dose amplification) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NBTXR3 consists of hafnium oxide nanoparticles that accumulate preferentially in tumor tissue. When exposed to ionizing radiation, these nanoparticles amplify the local dose deposition and generate secondary electrons that increase DNA damage and cell death in cancer cells. This mechanism allows for improved therapeutic efficacy of standard radiotherapy regimens.
Approved indications
- Locally advanced squamous cell carcinoma of the head and neck (in combination with radiotherapy)
- Soft tissue sarcoma (in combination with radiotherapy)
Common side effects
- Mucositis
- Dermatitis
- Dysphagia
- Fatigue
- Radiation-related toxicity (enhanced)
Key clinical trials
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC (PHASE3)
- A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-90301900 (NBTXR3) CI brief — competitive landscape report
- JNJ-90301900 (NBTXR3) updates RSS · CI watch RSS
- Johnson & Johnson Enterprise Innovation Inc. portfolio CI